Download PDF
Anästhesiol Intensivmed Notfallmed Schmerzther 2014; 49(6): 360-366
DOI: 10.1055/s-0034-1383887
Fachwissen
Anästhesiologie & Intensivmedizin
© Georg Thieme Verlag Stuttgart · New York

Kasuistik mit Literaturübersicht – Protamingabe bei Patientin mit Fischeiweißallergie

Risk factors for adverse reactions after protamine administration in adult patients undergoing cardiac surgery- a case report and literature review.
Simone Brück
,
Christian Skrabal
,
Karl Träger
,
Helmut Reinelt
Further Information

Publication History

Publication Date:
08 July 2014 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Protamin wird routinemäßig zur Neutralisierung der Antikoagulation mit Heparin bei großen herz- und gefäßchirurgischen Eingriffen nach extrakorporaler Zirkulation (EKZ) eingesetzt. Zwischenfälle nach Protamingabe sind selten. Wenn sie auftreten, verlaufen sie häufig katastrophal. Anhand des Fallberichtes einer Patientin mit Fischeiweißallergie und einer Literaturübersicht werden Risikofaktoren für Zwischenfälle nach Protamingabe sowie das perioperative Management und Outcome bei entsprechendem Risikoprofil dargestellt.

Abstract

Protamine is a protein mainly used to reverse anticoagulant effects of heparin during cardiac or vascular surgery with extracorporeal circulation. Adverse events after protamine administration are rare but if they occur they can be catastrophic. Based on a case report with an elective cardiac surgery patient with known allergy to fish, we discuss the related events and risk factors for an adverse reaction after protamine. The patient management and its outcome are presented.

Kernaussagen

  • Protamin ist ein Protein, das vorwiegend aus dem Sperma bestimmter Lachsarten isoliert wird. In der Medizin wird es zur Neutralisierung der Heparinwirkung nach großen herz- und gefäßchirurgischen Eingriffen eingesetzt.

  • Unverträglichkeiten sind selten und äußern sich als Hypotension, pulmonale Vasokonstriktion und allergische Reaktionen. Patienten mit insulinpflichtigem Diabetes mellitus und der Einnahme von NPH-Insulin, einer Allergie auf Fischeiweiß oder Patienten mit Z.n. Vasektomie haben ein erhöhtes Risiko, auf eine Protamingabe zu reagieren.

  • Bei Patienten mit bekannter Reaktion auf Protamin soll die Substanz möglichst vermieden werden. Der Transfusionsbedarf kann durch den Einsatz eines Cell-Savers zur Wiederaufbereitung des Drainageblutes sowie ein gezieltes Gerinnungsmanagement (ROTEM-gesteuert) reduziert werden. Je nach Befund- und Patientenkonstellation sind auch alternative OP-Verfahren wie Off-Pump-Chirurgie oder TAVI mit geringerem Heparinbedarf und Verzicht auf eine Antagonisierung zu diskutieren.

  • In der Literatur sind als Alternativen zu Heparin in der Herzchirurgie Bivalirudin, Argatroban oder eine Kombination von unfraktioniertem Heparin mit GP IIb/IIIa-Inhibitoren beschrieben.

  • Sollte die Gabe von Protamin unumgänglich sein, ist eine präoperative Testung mittels Hauttest oder – sofern verfügbar – mittels Agarose-RAST-Test auf Protamin-IgE-Antikörper dringend anzuraten. Die H1- und H2-Blocker Clemastin und Ranitidin sowie Glukokortikoide (Prednisolon) sollten bei unklaren Fällen vor Applikation von Protamin verabreicht werden. Die Infusion von Protamin muss grundsätzlich langsam erfolgen.

Schlüsselwörter:

Protamin - Fischallergie - ExtrakorporaleZirkulation

Keywords:

Protamine - fish allergy - extracorporeal circulation

Ergänzendes Material

 

  • Literatur

  • 1 http://www.medtronic.com/for-healthcare-professionals/products-therapies/cardiovascular/cardiopulmonary-products/balance-biosurface Stand am 04.02.2014
    PubMed
  • 2 Porsche R, Brenner ZR. Allergy to protamine sulfate. Heart Lung J Crit Care 1999; 28: 418-428
    PubMedGoogle Scholar
  • 3 Collins C, O'Donnell A. Does an allergy to fish pre-empt an adverse protamine reaction? A case report and a literature review. Perfusion 2008; 23: 369-372
    CrossrefPubMedGoogle Scholar
  • 4 Gupta SK, Veith FJ, Ascer E et al. Anaphylactoid reactions to protamine: an often lethal complication in insulin-dependent diabetic patients undergoing vascular surgery. J VascSurg 1989; 9: 342-350
    PubMedGoogle Scholar
  • 5 Morel DR, Zapol WM, Thomas SJ et al. C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin. Anesthesiology 1987; 66: 597-604
    CrossrefPubMedGoogle Scholar
  • 6 Weiler JM, Gellhaus MA, Carter JG et al. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. J Allergy ClinImmunol 1990; 85: 713-719
    CrossrefPubMedGoogle Scholar
  • 7 Schapira M, Christman BW. Neutralization of heparin by protamine. Time for a change?. Circulation 1990; 82: 1877-1879
    CrossrefPubMedGoogle Scholar
  • 8 Lowenstein E, Johnston WE, Lappas DG et al. Catastrophic pulmonary vasoconstriction associated with protamine reversal of heparin. Anesthesiology 1983; 59: 470-473
    CrossrefPubMedGoogle Scholar
  • 9 Cormack JG, Levy JH. Adverse reactions to protamine. Coron Artery Dis 1993; 4: 420-425
    CrossrefPubMedGoogle Scholar
  • 10 Weiss ME, Nyhan D, Peng ZK et al. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med 1989; 320: 886-892
    CrossrefPubMedGoogle Scholar
  • 11 Levy JH, Schwieger IM, Zaidan JR et al. Evaluation of patients at risk for protamine reactions. J ThoracCardiovascSurg 1989; 98: 200-204
    PubMedGoogle Scholar
  • 12 Best N, Sinosich MJ, Teisner B et al. Complement activation during cardiopulmonary bypass by heparin-protamine interaction. Br J Anaesth 1984; 56: 339-343
    CrossrefPubMedGoogle Scholar
  • 13 Kirklin JK, Chenoweth DE, Naftel DC et al. Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. Ann ThoracSurg 1986; 41: 193-199
    CrossrefPubMedGoogle Scholar
  • 14 Park KW. Protamine and protamine reactions. IntAnesthesiolClin 2004; 42: 135-145
    PubMedGoogle Scholar
  • 15 Rent R, Ertel N, Eisenstein R et al. Complement activation by interaction of polyanions and polycations. I. Heparin-protamine induced consumption of complement. J ImmunolBaltimMd 1975; 114: 120-124
    PubMedGoogle Scholar
  • 16 Chu Y-Q, Cai L-J, Jiang D-C et al. Allergic shock and death associated with protamine administration in a diabetic patient. ClinTher 2010; 32: 1729-1732
    PubMedGoogle Scholar
  • 17 Panos A, Orrit X, Chevalley C et al. Dramatic post-cardiotomy outcome, due to severe anaphylactic reaction to protamine. Eur J Cardio-ThoracSurg Off J EurAssoc Cardio-ThoracSurg 2003; 24: 325-327
    PubMedGoogle Scholar
  • 18 Levy JH, Zaidan JR, Faraj B. Prospective evaluation of risk of protamine reactions in patients with NPH insulin-dependent diabetes. AnesthAnalg 1986; 65: 739-742
    PubMedGoogle Scholar
  • 19 Sharath MD, Metzger WJ, Richerson HB et al. Protamine-induced fatal anaphylaxis. Prevalence of antiprotamine immunoglobulin E antibody. J ThoracCardiovascSurg 1985; 90: 86-90
    PubMedGoogle Scholar
  • 20 Adourian U, Shampaine EL, Hirshman CA et al. High-titer protamine-specific IgG antibody associated with anaphylaxis: report of a case and quantitative analysis of antibody in vasectomized men. Anesthesiology 1993; 78: 368-372
    CrossrefPubMedGoogle Scholar
  • 21 Knape JT, Schuller JL, de Haan P et al. An anaphylactic reaction to protamine in a patient allergic to fish. Anesthesiology 1981; 55: 324-325
    CrossrefPubMedGoogle Scholar
  • 22 Olsson P, Lagergren H, Ek S. The elimination from plasma of intravenous heparin. An experimental study on dogs and humans. Acta Med Scand 1963; 173: 619-630
    PubMedGoogle Scholar
  • 23 de Swart CA, Nijmeyer B, Roelofs JM et al. Kinetics of intravenously administered heparin in normal humans. Blood 1982; 60: 1251-1258
    PubMedGoogle Scholar
  • 24 Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119
    PubMedGoogle Scholar
  • 25 Estes JW. Clinical pharmacokinetics of heparin. ClinPharmacokinet 1980; 5: 204-220
    PubMedGoogle Scholar
  • 26 Loew A, Riess H. [Pharmacologic thromboprophylaxis in critically ill patients]. AnästhesiolIntensivmedNotfallmedizinSchmerzther AINS 2012; 47
    PubMedGoogle Scholar
  • 27 Markwardt F, Nowak G, Stürzebecher U et al. Studies on the pharmacokinetics of hirudin. BiomedBiochim Acta 1987; 46: 237-244
    PubMedGoogle Scholar
  • 28 Koster A, Rosendahl U, von Hodenberg E et al. Management of protamine allergy with bivalirudin during coronary artery revascularization. Ann ThoracSurg 2010; 90: 276-277
    CrossrefPubMedGoogle Scholar
  • 29 Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J ClinPharmacol 2011; 72: 581-592
    PubMedGoogle Scholar
  • 30 Alban S. [Pharmacology of heparins and direct anticoagulants]. Hämostaseologie 2008; 28: 400-420
    PubMedGoogle Scholar
  • 31 Lettino M, Toschi V. Direct antithrombins: new perspectives in cardiovascular medicine. Curr Med ChemCardiovascHematol Agents 2004; 2: 267-275
    PubMedGoogle Scholar
  • 32 Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. ThrombHaemost 2008; 99: 819-829
    PubMedGoogle Scholar
  • 33 Fischer K-G. Hirudin in renal insufficiency. SeminThrombHemost 2002; 28: 467-482
    PubMedGoogle Scholar
  • 34 Lubenow N, Greinacher A. Hirudin in heparin-induced thrombocytopenia. SeminThrombHemost 2002; 28: 431-438
    PubMedGoogle Scholar
  • 35 Merry AF, Raudkivi PJ, Middleton NG et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann ThoracSurg 2004; 77
    PubMedGoogle Scholar
  • 36 Palmer GJ, Sankaran IS, Sparkman GM et al. Routine use of the direct thrombin inhibitor bivalirudin for off-pump coronary artery bypass grafting is safe and effective. Heart Surg Forum 2008; 11: 24-29
    CrossrefPubMedGoogle Scholar
  • 37 Dyke CM, Smedira NG, Koster A et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J ThoracCardiovascSurg 2006; 131: 533-539
    PubMedGoogle Scholar
  • 38 Pieri M, Agracheva N, Bonaveglio E et al. Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study. J CardiothoracVascAnesth 2013; 27: 30-34
    PubMedGoogle Scholar
  • 39 Van De Car DA, Rao SV, Ohman EM. Bivalirudin: a review of the pharmacology and clinical application. Expert Rev CardiovascTher 2010; 8: 1673-1681
    PubMedGoogle Scholar
  • 40 Ranucci M, Ballotta A, Kandil H et al. Surgical and Clinical Outcome Research Group. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care LondEngl 2011; 15
    PubMedGoogle Scholar
  • 41 Linkins L-A, Dans AL, Moores LK et al. American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141
    PubMedGoogle Scholar
  • 42 De Servi S, Mariani G, Mariani M et al. The bivalirudin paradox: high evidence, low use. J Cardiovasc Med Hagerstown Md 2013; 14: 334-341
    PubMedGoogle Scholar
  • 43 Babuin L, Pengo V. Argatroban in the management of heparin-induced thrombocytopenia. Vasc Health Risk Manag 2010; 6: 813-819
    PubMedGoogle Scholar
  • 44 Phillips MR, Khoury AI, Ashton RF et al. The dosing and monitoring of argatroban for heparin-induced thrombocytopenia during extracorporeal membrane oxygenation: a word of caution. Anaesth Intensive Care 2014; 42: 97-98
    PubMedGoogle Scholar
  • 45 Follis F, Filippone G, Montalbano G et al. Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative?. Interact CardiovascThoracSurg 2010; 10: 592-596
    PubMedGoogle Scholar
  • 46 Koster A, Kukucka M, Bach F et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology 2001; 94: 245-251
    CrossrefPubMedGoogle Scholar
  • 47 Durand M, Lecompte T, Hacquard M et al. Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade. Eur J Cardio-ThoracSurg Off J EurAssoc Cardio-ThoracSurg 2008; 34: 687-689
    PubMedGoogle Scholar
  • 48 Kikura M, Lee MK, Levy JH. Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass. AnesthAnalg 1996; 83: 223-227
    PubMedGoogle Scholar
  • 49 Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990; 76: 1680-1697
    PubMedGoogle Scholar
  • 50 Englberger L, Streich M, Tevaearai H et al. Different anticoagulation strategies in off-pump coronary artery bypass operations: a European survey. Interact CardiovascThoracSurg 2008; 7: 78-82
    PubMedGoogle Scholar
  • 51 Adler K, Pullmann B, Byhahn C. [Anesthesia in endoscopic and percutaneous procedures in cardio-thoracic and cardiovascular interventions, Part 1– percutaneous aortic valve replacement and mitral valve repair]. AnästhesiolIntensivmedNotfallmedizinSchmerzther 2012; 47
    PubMedGoogle Scholar
  • 52 Linke A, Woitek F, Merx MW et al. Valve-in-valve implantation of Medtronic CoreValve prosthesis in patients with failing bioprosthetic aortic valves. CircCardiovascInterv 2012; 5: 689-697
    PubMedGoogle Scholar
  • 53 Godino C, Maisano F, Montorfano M et al. Outcomes after transcatheter aortic valve implantation with both Edwards-SAPIEN and CoreValve devices in a single center: the Milan experience. JACC CardiovascInterv 2010; 3: 1110-1121
    PubMedGoogle Scholar
  • 54 Horrow JC. Protamine allergy. J CardiothoracAnesth 1988; 2: 225-242
    PubMedGoogle Scholar
  • 55 Conahan 3rd TJ, Andrews RW, MacVaugh 3rd H. Cardiovascular effects of protamine sulfate in man. AnesthAnalg 1981; 60: 33-36
    PubMedGoogle Scholar
  • 56 Ranft A, Kochs EF. [Treatment of anaphylactic reactions: a review of guidelines and recommendations]. AnästhesiolIntensivmedNotfallmedizinSchmerzther 2004; 39: 2-9
    PubMedGoogle Scholar
  • 57 Johnson RF, Peebles RS. Anaphylactic shock: pathophysiology, recognition, and treatment. SeminRespirCrit Care Med 2004; 25: 695-703
    PubMedGoogle Scholar
  • 58 Handel M, Sell S, Heeg P. Infektionsrisiko bei postoperativer autogener Retransfusion von Drainageblut. Operative Orthopädie und Traumatologie 2001; 13: 74-74
    CrossrefPubMedGoogle Scholar
  • 59 Yarham G, Clements A, Oliver M et al. Mulholland J. Evaluating the “next generation” of cell salvage – will it make a difference?. Perfusion 2011; 26: 263-270
    CrossrefPubMedGoogle Scholar